A dose-response meta-analysis for quantifying relative efficacy of biologics in rheumatoid arthritis

Clinical Pharmacology and Therapeutics

Volumn 90, Issue 6, 2011, Pages 828-835

  Mandema, J W ^a   Salinger, D H ^b   Baumgartner, S W ^c,d   Gibbs, M A ^b  

^a Quantitative Solutions Inc   (United States)

^b AMGEN INC   (United States)

^c AMGEN INC   (United States)

^d Arrdea Biosciences Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ADALIMUMAB; CERTOLIZUMAB PEGOL; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RITUXIMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ARTICLE; CLINICAL PROTOCOL; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; HUMAN; MEDICAL SOCIETY; META ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TUMOR NECROSIS FACTOR-ALPHA;

EID: 81355123266     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.256     Document Type: Article

References (11)

1. Sutton, A., Ades, A.E., Cooper, N. & Abrams, K. Use of indirect and mixed treatment comparisons for technology assessment. Pharmacoeconomics 26, 753-767 (2008).
2. Hochberg, M.C., Tracy, J.K., Hawkins-Holt, M. & Flores, R.H. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. Ann. Rheum. Dis. 62 (suppl. 2), ii13-ii16 (2003).
3. Alonso-Ruiz, A., Pijoan, J.I., Ansuategui, E., Urkaregi, A., Calabozo, M. & Quintana, A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet. Disord. 9, 52 (2008).
4. Salliot, C. et al. Indirect comparisons of the efficacy of biological antirheumatic agents in rheumatoid arthritis in patients with an inadequate response to conventional disease-modifying antirheumatic drugs or to an anti-tumour necrosis factor agent: a meta-analysis. Ann. Rheum. Dis. 70, 266-271 (2011).
5. Mandema, J.W., Cox, E. & Alderman, J. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain-results of a model-based meta-analysis that accounts for encapsulation. Cephalalgia 25, 715-725 (2005). (Pubitemid 41208313)
6. Mandema, J.W. et al. Model-based development of gemcabene, a new lipidaltering agent. AAPS J. 7, E513-E522 (2005).
7. Gibbs, J.P. et al. Quantitative model of the relationship between dipeptidyl peptidase-4 (DPP-4) inhibition and response: meta-analysis of alogliptin, saxagliptin, sitagliptin, and vildagliptin efficacy results. J. Clin. Pharmacol., in press.
8. Bongartz, T., Sutton, A.J., Sweeting, M.J., Buchan, I., Matteson, E.L. & Montori, V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295, 2275-2285 (2006). (Pubitemid 43736578)
9. Keystone, E. et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Arthritis Rheum. 58, 3319-3329 (2008).
10. Smolen, J. et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. Ann. Rheum. Dis. 68, 797-804 (2009).
11. Felson, D.T. et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. Arthritis Rheum. 36, 729-740 (1993). (Pubitemid 23175613)